Forbes – The risk of rare heart inflammation following Covid-19 vaccination is “very low,” and much smaller than the risks linked to a coronavirus infection itself, according to a peer reviewed study published on Monday in Lancet Respiratory Medicine.
The study underscores the benefits and safety profile of Covid vaccines as many countries begin to roll out second booster doses to protect against new waves of the virus.
The overall risk of myopericarditis—the inflammation of the heart muscle and lining around the heart—following Covid vaccination is low and not significantly different from people receiving vaccines against other diseases, according to the analysis of 22 studies using international databases from 1947 through December 2021.
The analysis, which covered around 395 million doses of Covid-19 vaccine, including around 300 million mRNA vaccines by Pfizer and Moderna and nearly 10 million doses of non-Covid vaccines, found 18 cases of myopericarditis per million doses of Covid-19 vaccine compared to 56 cases per million doses for non-Covid vaccinations like influenza.
The risk of myopericarditis was nearly four times higher among those receiving an mRNA Covid vaccine versus a non-mRNA Covid vaccine and among those getting their second dose compared to a first or third, the researchers found.
“Covid-19 carries a more significant risk of heart issues alongside a litany of other problems.”
The risk was notably higher among young men under 30, who had rates 10 times higher than women of the same age, the researchers said, with the rate for men over 30 around three times as high than for women over 30 … READ MORE.